CO4700433A1 - Nuevas sulfonamidas heterociclicas oxigenadas inhibidoras de la proteasa aspartilo - Google Patents

Nuevas sulfonamidas heterociclicas oxigenadas inhibidoras de la proteasa aspartilo

Info

Publication number
CO4700433A1
CO4700433A1 CO96019067A CO96019067A CO4700433A1 CO 4700433 A1 CO4700433 A1 CO 4700433A1 CO 96019067 A CO96019067 A CO 96019067A CO 96019067 A CO96019067 A CO 96019067A CO 4700433 A1 CO4700433 A1 CO 4700433A1
Authority
CO
Colombia
Prior art keywords
group
optionally
independently selected
het
alkyl
Prior art date
Application number
CO96019067A
Other languages
English (en)
Inventor
Roger D Tung
Original Assignee
Vertex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma Inc filed Critical Vertex Pharma Inc
Publication of CO4700433A1 publication Critical patent/CO4700433A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un compuesto de fórmula I:en el cual:cada R1 está independientemente seleccionado del grupo que consiste en -C(O)-, -S(O)2 - -C(O)-C(O)-, -O-C(O)-O -S(O)2 , -NR2 -S(O)2 , -NR2 -C(O)- y -NR2 -C(O)-C(O)-; cada A está independientemente seleccionado del grupo que consiste en heterociclos monocíclicos oxigenados no aromáticos de 5-7 miembros que contienen de 1-3 oxígenos endocíclicos, que pueden estar opcionalmente benzofusionados, opcionalmente enlazados a través de un ligador alquilo C1 -C3 y opcionalmente fusionados con un heterociclo monocíclico de 5-7 miembros que contiene desde 1-2 heteroátomos endocíclicos, y del cual se han excluído expresamente tetrahidrofurano y tetrahidrofurotetrahidrofurano; cada Het está independientemente seleccionado del grupo que consiste en carbociclo C3 -C7 ; arilo C6 -C10 ; fenilo fusionado con heterociclo; y heterociclo; en el cual cualquier miembro de dicho Het puede estar opcionalmente substituído con uno o más substituyentes seleccionados del grupo que consiste en oxo, -OR2 , -R2 , -N(R2 )(R2 ), -NHOH, -R2 -OH, -CN, CO2 R2 , -C(O)-R2 , -C(O)NR2 -(R2 ), -S(O)2 - (NR2 )(R2 ), N(R2 )- C(O)-R2 , -S(O)n -R2 , OCF3 , -S(O)n -R6 , (-N(R2 )- S(O)2 (R2 ), halo, -CF3 , -NO2 , -R6 y -O-R6 ; cada R2 está independientemente seleccionado del grupo que consiste en H y alquilo C1 -C3 opcionalmente substituído con R6 ;cada R3 está independientemente seleccionado del grupo que consiste en H, Het, alquilo C1 -C6 y alquenilo C2 -C6 donde cualquier miembro de dicho R3 , excepto H, puede estar opcionalmente substituído con uno o más substituyentes seleccionados del grupo que consiste en -OR2 , -C(O)--NH(R2 ), -S(O)n -(R2 )(R2 ) Het, -CN, -SR2 , CO2 R2 , NR2 -C(O)R2 ; cada n es independientemente 1 ó 2;cada D y D´ está independientemente seleccionado del grupo que consiste en R6 ; alquilo C1 -C5 que puede estar opcionalmente substituído con uno o más grupos seleccionados de -OR2 , -R3 , -S-R6 y R6 ; alquenilo C2 -C4 que puede estar opcionalmente substituido con uno más grupos seleccionados del grupo que consiste en -OR2 , -R3 , -O-R6 y R6 ; y carbociclo C3 -C6 , que puede estar opcionalmente substituido con o fusionado con R6 ; ...
CO96019067A 1995-04-19 1996-04-19 Nuevas sulfonamidas heterociclicas oxigenadas inhibidoras de la proteasa aspartilo CO4700433A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/424,810 US5691372A (en) 1995-04-19 1995-04-19 Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease

Publications (1)

Publication Number Publication Date
CO4700433A1 true CO4700433A1 (es) 1998-12-29

Family

ID=23683966

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96019067A CO4700433A1 (es) 1995-04-19 1996-04-19 Nuevas sulfonamidas heterociclicas oxigenadas inhibidoras de la proteasa aspartilo

Country Status (35)

Country Link
US (2) US5691372A (es)
EP (3) EP1136479B1 (es)
JP (1) JP4240532B2 (es)
KR (1) KR100485237B1 (es)
CN (1) CN1110491C (es)
AP (2) AP9600827A0 (es)
AR (1) AR004663A1 (es)
AT (3) ATE314360T1 (es)
AU (1) AU712913B2 (es)
BG (1) BG102041A (es)
BR (1) BR9608033A (es)
CA (1) CA2217745C (es)
CO (1) CO4700433A1 (es)
CZ (1) CZ329497A3 (es)
DE (3) DE69618779T2 (es)
DK (1) DK0833826T3 (es)
EA (1) EA000906B1 (es)
EE (1) EE9700254A (es)
ES (3) ES2351970T3 (es)
GE (1) GEP20001915B (es)
HK (2) HK1092791A1 (es)
HU (1) HUP9801948A3 (es)
IL (1) IL117962A0 (es)
IS (1) IS4575A (es)
MY (1) MY115797A (es)
NO (1) NO974744D0 (es)
NZ (1) NZ307342A (es)
PE (1) PE43697A1 (es)
PL (1) PL322904A1 (es)
PT (1) PT833826E (es)
SK (1) SK143097A3 (es)
TR (1) TR199701194T1 (es)
TW (1) TW404945B (es)
WO (1) WO1996033187A1 (es)
ZA (1) ZA962891B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
KR100336699B1 (ko) 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
JP2002515051A (ja) 1996-12-31 2002-05-21 ジーピーアイ エヌアイエル ホールディングス インコーポレイテッド ヘテロ環式チオエステルのｎ−結合スルホンアミド
CA2289654A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2092599A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU767728B2 (en) * 1998-06-19 2003-11-20 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
ATE500823T1 (de) 1998-06-23 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Arzneimittel zur behandlung von hiv-infizierten säugetieren
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
TWI260322B (en) 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
SI1159278T1 (sl) * 1999-02-12 2006-06-30 Vertex Pharma Inhibitorji aspartil proteaze
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
SK287153B6 (sk) * 1999-10-06 2010-01-07 Tibotec Pharmaceuticals Ltd. Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5- ylsulfonyl)(izobutyl)amino]1-benzyl-2-hydroxypropyl}karbamát, jeho použitie a farmaceutický prípravok s jeho obsahom
US7135465B2 (en) 2000-03-30 2006-11-14 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
SK288232B6 (sk) * 2001-04-09 2014-11-04 Tibotec Pharmaceuticals Ltd. 2-(substituovaný amino)benzoxazolsulfónamidový derivát, jeho aplikácie ako liečiva, farmaceutická kompozícia s jeho obsahom a spôsob in vitro inhibície retrovírusovej replikácie
EP1472536A4 (en) * 2002-01-07 2007-02-14 Sequoia Pharmaceuticals VERSATILE INHIBITORS
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
AU2003300375A1 (en) * 2002-10-11 2004-05-04 Semplastics, L.L.C. Retaining ring for use on a carrier of a polishing apparatus
CA2507484A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US20080194554A1 (en) * 2005-03-11 2008-08-14 Mclean Ed W Hiv Protease Inhibitors
JP2007202679A (ja) * 2006-01-31 2007-08-16 Juki Corp ミシンの糸調子装置
JP2007202833A (ja) * 2006-02-02 2007-08-16 Juki Corp ミシンの糸調子装置
EP2491785A1 (en) * 2006-11-21 2012-08-29 Purdue Research Foundation Method and compositions for treating HIV infections
EP2244571A4 (en) 2008-01-17 2014-02-19 Purdue Research Foundation SMALL INHIBITORY MOLECULES OF HIV PROTEASES
US8791135B2 (en) 2008-07-01 2014-07-29 Purdue Research Foundation Nonpeptide HIV-1 protease inhibitors
EP2304043A4 (en) 2008-07-09 2012-05-30 Purdue Research Foundation HIV PROTEASE INHIBITORS AND METHOD FOR THEIR USE
CN105272991B (zh) * 2014-06-26 2017-11-07 成都中医药大学 一种化合物晶型
US11090030B2 (en) 2016-11-10 2021-08-17 Leltek Inc. Ultrasound apparatus and ultrasound emission method

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) * 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) * 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) * 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) * 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) * 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) * 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CH676988A5 (es) * 1987-01-21 1991-03-28 Sandoz Ag
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) * 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) * 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2084087A1 (en) * 1990-06-01 1991-12-02 Prabhakar Kondaji Jadhav 1,4-diamino 2,3-dihydroxy butanes
TW225540B (es) * 1990-06-28 1994-06-21 Shionogi & Co
EP0558673B1 (en) * 1990-11-19 1996-04-17 Monsanto Company Retroviral protease inhibitors
AU662114B2 (en) * 1990-11-19 1995-08-24 Monsanto Company Retroviral protease inhibitors
ATE147378T1 (de) * 1990-11-19 1997-01-15 Monsanto Co Retrovirale protease inhibitoren
EP0813868B1 (en) * 1990-11-19 2005-06-01 Monsanto Company Retroviral protease inhibitors
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
DE69224703T2 (de) * 1991-11-08 1998-10-15 Merck & Co Inc HIV-Protease-Inhibitoren verwendbar in der AIDS-Behandlung
EP0641333B1 (en) * 1992-05-20 1996-08-14 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
WO1993023379A1 (en) * 1992-05-21 1993-11-25 Monsanto Company Retroviral protease inhibitors
KR100336699B1 (ko) * 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
DK0656888T3 (da) * 1992-08-25 1998-02-09 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfonamider, anvendelige som retrovirale protease-inhibitorer
US5463104A (en) * 1992-08-25 1995-10-31 G. D. Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
AU5547094A (en) * 1992-10-30 1994-05-24 G.D. Searle & Co. Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
EP0666843B1 (en) * 1992-10-30 1999-08-18 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
AU6135294A (en) * 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
JP3419539B2 (ja) * 1993-02-17 2003-06-23 中外製薬株式会社 インドリン−２−オン誘導体
DE69415326T2 (de) * 1993-08-24 1999-06-02 Searle & Co Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій

Also Published As

Publication number Publication date
AU712913B2 (en) 1999-11-18
ATE314360T1 (de) 2006-01-15
DE69635679T2 (de) 2006-08-31
CA2217745C (en) 2011-07-05
DE69618779T2 (de) 2002-08-29
ATE479674T1 (de) 2010-09-15
KR19990007823A (ko) 1999-01-25
ATE212344T1 (de) 2002-02-15
KR100485237B1 (ko) 2005-09-30
EP1637528B1 (en) 2010-09-01
AP9701104A0 (en) 1997-10-31
NO974744L (no) 1997-10-14
EP1637528A1 (en) 2006-03-22
HUP9801948A3 (en) 2002-04-29
EP1136479A1 (en) 2001-09-26
CN1110491C (zh) 2003-06-04
NO974744D0 (no) 1997-10-14
AR004663A1 (es) 1999-03-10
NZ307342A (en) 1999-04-29
EP1136479B1 (en) 2005-12-28
US5990155A (en) 1999-11-23
EP0833826B1 (en) 2002-01-23
AP9600827A0 (en) 1997-10-17
PL322904A1 (en) 1998-03-02
TW404945B (en) 2000-09-11
SK143097A3 (en) 1998-03-04
EP0833826A1 (en) 1998-04-08
HUP9801948A2 (hu) 1999-09-28
WO1996033187A1 (en) 1996-10-24
ES2256117T3 (es) 2006-07-16
IS4575A (is) 1997-10-02
ZA962891B (en) 1996-10-15
GEP20001915B (en) 2000-01-05
ES2171670T3 (es) 2002-09-16
AP862A (en) 2000-08-04
EE9700254A (et) 1998-04-15
DE69618779D1 (de) 2002-03-14
PT833826E (pt) 2002-06-28
DE69638252D1 (de) 2010-10-14
DK0833826T3 (da) 2002-05-06
CA2217745A1 (en) 1996-10-24
CN1184474A (zh) 1998-06-10
AU5665596A (en) 1996-11-07
BR9608033A (pt) 1999-01-12
JPH11504628A (ja) 1999-04-27
JP4240532B2 (ja) 2009-03-18
ES2351970T3 (es) 2011-02-14
HK1092791A1 (en) 2007-02-16
CZ329497A3 (cs) 1998-03-18
US5691372A (en) 1997-11-25
IL117962A0 (en) 1996-08-04
DE69635679D1 (de) 2006-02-02
EA199700330A1 (ru) 1998-04-30
HK1009811A1 (en) 1999-06-11
TR199701194T1 (xx) 1998-03-21
PE43697A1 (es) 1997-10-11
MY115797A (en) 2003-09-30
BG102041A (en) 1998-09-30
EA000906B1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
CO4700433A1 (es) Nuevas sulfonamidas heterociclicas oxigenadas inhibidoras de la proteasa aspartilo
CO4990992A1 (es) Profarmacos de compuestos de sulfonamida como inhibidores de aspartil proteasa
AR105836A1 (es) Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk
AR113765A1 (es) Inhibidores de la proteasa del vih
AR055144A1 (es) Inhibidor de secrecion acida
PE20220141A1 (es) Inhibidores de la proteina tirosina fosfatasa
AR123127A1 (es) Compuestos y métodos de uso
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
PE20011055A1 (es) Compuestos de imidazolidin 2,4-diona sustituida y procedimientos para su preparacion
AR118724A1 (es) Inhibidores de dihidroorotato deshidrogenasa
CO6260136A2 (es) Metodo para preparar derivados de 5-haloalquil-4,5-dihidroisoxazol
BR0114657A (pt) Compostos de benzamida e seu uso
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR118613A1 (es) Compuestos de oxadiazol para controlar o prevenir hongos fitopatogénicos
AR115085A1 (es) DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk)
CO5580762A2 (es) Analogos de lipoxina a4
ES2087097T3 (es) Derivados de acidos fenilcarboxilicos que contienen un heterociclo.
AR111594A1 (es) Agentes inhibidores de la tirosina quinasa de bruton
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR114679A1 (es) Compuestos heterocíclicos fungicidas
CO6150150A2 (es) Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica
AR102731A1 (es) Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor
CO4940477A1 (es) Inhibidores de proteasa
AR119376A1 (es) Compuestos heterocíclicos